ReviewAdvanced materials (Deerfield Beach, Fla.)2021
Capturing Cytokines with Advanced Materials: A Potential Strategy to Tackle COVID-19 Cytokine Storm.
Review in Advanced materials (Deerfield Beach, Fla.), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 82 citations in OpenAlex.
- Immune monitoring, immune phenotyping, and precision intervention in severe pneumonia: current evidence and translational challenges.Frontiers in immunology · 2026Review
- From bench to bedside: the promise and roadblocks of extracellular vesicle therapeutics.Theranostics · 2026Review
- Saccharomyces cerevisiae as a Model for Reprogramming of Eukaryotic Cells: Implications for the Study of the Relationship Between Metabolism and Inflammation in Chronic Disease.Cell biochemistry and biophysics · 2025Article
- Nanoparticle approaches for manipulating cytokine delivery and neutralization.Frontiers in immunology · 2025Review
- Biomaterials for Modulating the Immune Microenvironment in Rheumatoid Arthritis.BME frontiers · 2025Review
- Fibroblasts in heterotopic ossification: mechanisms and therapeutic targets.International journal of biological sciences · 2025Review
- Nano-enhanced immunity: A bibliometric analysis of nanoparticles in vaccine adjuvant research.Human vaccines & immunotherapeutics · 2024Article
- Cytokine Storm in COVID-19: Insight into Pathological Mechanisms and Therapeutic Benefits of Chinese Herbal Medicines.Medicines (Basel, Switzerland) · 2024Review
- Inhalation delivery of dexamethasone with iSEND nanoparticles attenuates the COVID-19 cytokine storm in mice and nonhuman primates.Science advances · 2023Article
- Engineered Extracellular Vesicle-Delivered CRISPR/CasRx as a Novel RNA Editing Tool.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2023Article
- Regulating the microenvironment with nanomaterials: Potential strategies to ameliorate COVID-19.Acta pharmaceutica Sinica. B · 2023Review
- Functional nucleic acids as potent therapeutics against SARS-CoV-2 infection.Cell reports. Physical science · 2023Review
- 6-Shogaol and 10-Shogaol Synergize Curcumin in Ameliorating Proinflammatory Mediators via the Modulation of TLR4/TRAF6/MAPK and NFκB Translocation.Biomolecules & therapeutics · 2023Article
- Article
- Neutrophil heterogeneity and aging: implications for COVID-19 and wound healing.Frontiers in immunology · 2023Review
- Plasma polymerized bio-interface directs fibronectin adsorption and functionalization to enhance "epithelial barrier structure" formation via FN-ITG β1-FAK-mTOR signaling cascade.Biomaterials research · 2022Article
- Recent applications of immunomodulatory biomaterials for disease immunotherapy.Exploration (Beijing, China) · 2022Review
- A decoy microrobot that removes SARS-CoV-2 and its variants in wastewater.Cell reports. Physical science · 2022Article
- Peritoneal M2 macrophage-derived extracellular vesicles as natural multitarget nanotherapeutics to attenuate cytokine storms after severe infections.Journal of controlled release : official journal of the Controlled Release Society · 2022Article
- Lipid Nanoparticles for mRNA Delivery to Enhance Cancer Immunotherapy.Molecules (Basel, Switzerland) · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 5 institutions in 2 countries.
Funding
Abstract
The COVID-19 pandemic, induced by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has caused great impact on the global economy and people's daily life. In the clinic, most patients with COVID-19 show none or mild symptoms, while approximately 20% of them develop severe pneumonia, multiple organ failure, or septic shock due to infection-induced cytokine release syndrome (the so-called "cytokine storm"). Neutralizing antibodies targeting inflammatory cytokines may potentially curb immunopathology caused by COVID-19; however, the complexity of cytokine interactions and the multiplicity of cytokine targets make attenuating the cytokine storm challenging. Nonspecific in vivo biodistribution and dose-limiting side effects further limit the broad application of those free antibodies. Recent advances in biomaterials and nanotechnology have offered many promising opportunities for infectious and inflammatory diseases. Here, potential mechanisms of COVID-19 cytokine storm are first discussed, and relevant therapeutic strategies and ongoing clinical trials are then reviewed. Furthermore, recent research involving emerging biomaterials for improving antibody-based and broad-spectrum cytokine neutralization is summarized. It is anticipated that this work will provide insights on the development of novel therapeutics toward efficacious management of COVID-19 cytokine storm and other inflammatory diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.